- Programme launched to promote disease prevention
- Silicosis lung disease on the rise
- Hanoi hospital of lung disease inaugurates new tuberculosis laboratory
- Vitamin D deficiency may raise risk of certain autoimmune lung diseases: study
- 4th Asia Pacific Region Conference against TB and Lung Disease opens
Da Nang (VNA) – As many as 150 outpatient centres treating
chronic asthma and chronic obstructive pulmonary disease (COPD) will be built
at total investment of 1 million USD by AstraZeneca multinational
pharmaceutical and biopharmaceutical company under the “Health lung” programme.
The programme was launched by the Vietnam Medical Association, the Vietnam
Respiratory Society, the Vietnam Association against Tuberculosis and Lung
Diseases and AstraZeneca company in the central city of Da Nang on September
It aims to enhance management of asthma and COPD, contributing to reducing cases
According to President of the Vietnam Respiratory Society Ngo Quy Chau, people
diagnosed with COPD accounts for 4.2 percent of total population and most of
them are at the age of 40. However, only 29.1 percent of the asthma patients,
who make up 4.1 percent of total population, are taking medication while 39.7
percent have good control of the disease.
Along with cigarettes and environmental pollution, pulmonary tuberculosis has
increased risk of COPD, which puts a burden on society, Chau underlined.
Meanwhile, Le Thi Tuyet Lan, President of the Society of Asthma & Allergy
& Clinical Immunology and Vice President of the Vietnam Respiratory
Society, said that the outpatient treatment network will help reduce economic and
health care burdens for Vietnam.-VNA